Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avantor, Inc.AVTR · Entity 3546 | EVP, Biopharma Production | May 17, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avantor, Inc.
Report date May 17, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,032 |
Reported balance
After 2023-05-17 transaction · row 1
1 source rowRow 1 · 2023-05-17 · Tax withholding · Disposed 19,683 · Balance 89,032 F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2020 Filed Feb 25, 2020 22:21 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 24,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-20-000049 · wf-form4_158266928020210.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,868 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 21, 2021. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:03 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantStock Options (Right to Buy) · Derivative | 178,253 | $0.00 Strike: $18.45 | $0.00 |
DisclosureSEC source: 0001722482-20-000006 · wf-form4_157834819511454.xml · derivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,253 Underlying: Common Stock · 178,253 shares Expires 2030-01-02 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in three equal annual installments beginning on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:03 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 54,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-20-000006 · wf-form4_157834819511454.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,344 F1 · kind: Reflects a grant of restricted stock units that vest in three equal annual installments beginning on January 2, 2021. Read SEC document |
| May 21, 2019 Filed May 23, 2019 23:25 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 157,143 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014592 · doc4.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,143 F1 · kind: Reflects a grant of restricted stock units that vests as follows: (a) 50% vests on May 21, 2021, and (b) the remaining 50% vests in two equal annual installments beginning on May 21, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.